| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49c31e26df8ddf5cf3a13755f6323e60 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7125 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7125 |
| filingDate |
2020-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ff07f4a614bca061c5c54f0fd9b1f91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4a06210967b1b332f91a697ecddcfd6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_211d99165de249c88ffc2da2267cd1a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9665487fc47f83cfae2667ab324ce92f |
| publicationDate |
2022-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022088059-A1 |
| titleOfInvention |
Combined spherical nucleic acid and checkpoint inhibitor for antitumor therapy |
| abstract |
Aspects of the invention are directed to methods of treating cancer using a combination of spherical nucleic acids (SNAs) and a checkpoint inhibitor. The SNA molecule comprises a core oligonucleotide shell of CpG oligonucleotides positioned on the exterior of this core. The SNA is administered at a fixed dose of 2mg to a solid tumour or tumour lesion, and is administered within 24 hours of the checkpoint inhibitor administration. The SNA can also be administered at a dose of 700 mg-900 mg every 2 weeks. The SNA can also be a CpG linked via a spacer to the exterior surface of a liposome core of 40 nm or less diameter. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020248183-A1 |
| priorityDate |
2019-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |